# THE MITOCHONDRIAL DYNAMISM/FITNESS/BIOGENESIS INTERACTOME IN CARDIAC DISEASE

> **NIH NIH R35** · WASHINGTON UNIVERSITY · 2020 · $915,000

## Abstract

The mitochondrial dynamism/fitness/biogenesis interactome in cardiac disease
Dorn GW II
Abstract
 Cardiomyocyte mitochondria are essential providers of ATP that fuels contraction and normal
or reparative cardiomyocyte growth. Observationally, cardiomyocyte utilization of metabolic substrates
evolves during cardiac development from a fetal preference for carbohydrates to the normal adult
preference for fatty acids. In adult hearts, pathological reversion toward mitochondrial utilization of
carbohydrates is postulated to contribute to cardiac hypertrophy, heart failure and myocardial
infarction. However, our grasp of specific mechanisms that direct cardiac substrate utilization is
incomplete, and forced genetic production of cardiomyocyte mitochondria has not proven therapeutic
in experimental models of heart disease.
 Our conceptual breakthrough was that cardiac metabolism is not determined by a “master
regulator”, but is directed by the interplay between mitochondrial dynamism, fitness and biogenesis.
We posit that myocardial metabolic remodeling requires coordinated modulation of mitophagic
mitochondrial removal, biogenic mitochondrial replacement and fusion/fission-mediated mitochondrial
redistribution. By individually disrupting these pathways and defining the consequences on
mitochondrial, cell and organ functioning we determined how these three processes are co-regulated
and functionally-interdependent, therein defining a central role for Mfn2 as orchestrator of
mitochondrial fate (i.e. retention vs removal). By engineering artificial Mfn2 mutations and studying
damaging human Mfn2 mutations identified through DNA sequencing of cardiomyopathy cohorts we
are learning how each major process within the interactome is internally fine-tuned through modulation
of functionally opposing pairs. Specifically, Mfn-mediated mitochondrial fusion is opposed by Drp1-
mediated mitochondrial fission; PGC1-mediated biogenesis of fatty acid-catabolizing mitochondria is
opposed by PRC-mediated biogenesis of carbohydrate-catabolizing mitochondria; and mitochondrial
replication is opposed by Parkin-mediated mitochondrial elimination. Based on these insights, which
represent a convergence of the research aims of HL59888 (mito fusion) and HL128441 (mitophagy),
we developed novel genetic and biochemical tools, namely Separation-of-Function mutant Mfn2
proteins and cell-permeant peptides, to specifically manipulate mitochondrial dynamism or mitophagy
in vitro and in vivo. We will employ these new concepts and reagents to dissect the molecular
mechanisms that drive metabolic remodeling in normal and diseased hearts, and to develop
translatable means of optimally matching cardiac metabolism to pathophysiological status by “dialing-
in” mitochondrial quality and quantity via precision manipulations within the interactome.

## Key facts

- **NIH application ID:** 9841964
- **Project number:** 5R35HL135736-04
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Gerald W. Dorn
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $915,000
- **Award type:** 5
- **Project period:** 2017-01-16 → 2023-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9841964

## Citation

> US National Institutes of Health, RePORTER application 9841964, THE MITOCHONDRIAL DYNAMISM/FITNESS/BIOGENESIS INTERACTOME IN CARDIAC DISEASE (5R35HL135736-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9841964. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
